NCT07019259Recruiting
Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 23 May 2025
- Start date
- 30 Jun 2025
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Yale University
- Diseases
- Childhood cancers
- NCT number
- NCT07019259
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 30 Jun 2025 to the primary completion date, 30 Apr 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis of neuropathy prior to cancer treatment
Other illness
- Active cancer diagnosis or cancerous skin lesion
- Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.
Other
- Currently Pregnant or lactating (by patient report, at initiation or at any point of the study)
- Inability to sit still for at least 15 minutes
- Central nervous system tumor (due to lack of validated measures for CIPN in this population)
Who the study is looking for
- History of childhood cancer (\<21 years of age at diagnosis)
- Current age five years or older (due to availability of validated measures for CIPN in this age group)
- History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN
- CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors \<18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation)
Age in the registry: 5 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yale New Haven Health Smilow York Street Hospital Coordinator of this site? Confirm its status | New Haven | United States | Recruiting |
| Yale New Haven Health Park Avenue Medical Center Coordinator of this site? Confirm its status | Trumbull | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.